Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-Μg or 50-Μg Daily Doses
Clinical Therapeutics - United States
doi 10.1016/j.clinthera.2017.08.011
Full Text
Open PDFAbstract
Available in full text
Categories
Date
October 1, 2017
Authors
Publisher
Elsevier BV